Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma

Juntaro Matsuzaki,1,2 Hidekazu Suzuki3

ABSTRACT

Objective Circulating microRNAs (miRNAs) are promising biomarkers for the early detection of cancers. This study aimed to address potential circulating miRNAs to monitor the progression from Barrett’s oesophagus (BO) to oesophageal adenocarcinoma (OAC).

Design We comprehensively analysed tissue and serum miRNA expression profiles of BO mouse model (L2-interleukin-1β (IL-1β) mice) using microarray analysis. To validate the data from mice, a published dataset of human plasma miRNAs, consisting of eight patients with OAC, eight with BO and six healthy controls, was used (GSE51410).

Results We identified 20 upregulated miRNAs and 44 downregulated miRNAs both in tissues and in sera of 46-week-old mice compared with 28-week-old mice. Two of the 20 miRNAs (miR-128-3p and miR-328-3p) were upregulated, and five of the 44 miRNAs (miR-143-3p, miR-144-3p, miR-15a-5p, miR-1-3p and miR-133b) were downregulated in plasma of patients with OAC compared with plasma of patients with BO. Receiver operating characteristic curve analysis revealed that a prediction index calculated by the above-mentioned seven miRNAs could discriminate between patients with OAC and those without OAC with the area under the curve of 0.91, sensitivity of 1 and specificity of 0.75.

Conclusions Levels of the seven circulating miRNAs may represent the tissue miRNA levels and could be promising non-invasive biomarkers to evaluate the carcinogenic process of BO.

INTRODUCTION

Oesophageal adenocarcinoma (OAC) is one of the most dramatically increasing malignant diseases in Western countries. The incidence of OAC has increased around six times in the last four decades.1 Well-known causal factors of OAC are the presence of gastro-oesophageal reflux diseases and obesity and the absence of Helicobacter pylori infection.2–5 Barrett’s oesophagus (BO), which is histologically characterised by the replacement of the normal stratified squamous epithelium of the oesophagus with a columnar epithelium, is considered to be a precursor lesion of OAC.3,4 To improve patient survival and reduce disease burden, early-stage detection or preventing the progression of OAC from BO constitute the best options. Although endoscopic surveillance for patients with BO has been usually conducted, an absolute annual risk for the development of OAC from BO is only 0.12%.6 Therefore, considering the invasiveness, recommending conventional endoscopic screening procedure has been deemed controversial.7 Thus, identification of non-invasive risk stratification biomarkers to determine the risk of progression from BO to OAC may improve disease outcome and render patient management more efficient.

MicroRNAs (miRNAs) are a class of small non-coding endogenous RNAs, which are 18–25 nucleotides in length. They regulate gene expression at the post-translational level by guiding the RNA-induced silencing complex of OAC.8–10 To improve patient survival and reduce disease burden, early-stage detection or preventing the progression of OAC from BO constitute the best options. Although endoscopic surveillance for patients with BO has been usually conducted, an absolute annual risk for the development of OAC from BO is only 0.12%.6 Therefore, considering the invasiveness, recommending conventional endoscopic screening procedure has been deemed controversial.7 Thus, identification of non-invasive risk stratification biomarkers to determine the risk of progression from BO to OAC may improve disease outcome and render patient management more efficient.

MicroRNAs (miRNAs) are a class of small non-coding endogenous RNAs, which are 18–25 nucleotides in length. They regulate gene expression at the post-translational level by guiding the RNA-induced silencing complex of OAC.8–10 To improve patient survival and reduce disease burden, early-stage detection or preventing the progression of OAC from BO constitute the best options. Although endoscopic surveillance for patients with BO has been usually conducted, an absolute annual risk for the development of OAC from BO is only 0.12%.6 Therefore, considering the invasiveness, recommending conventional endoscopic screening procedure has been deemed controversial.7 Thus, identification of non-invasive risk stratification biomarkers to determine the risk of progression from BO to OAC may improve disease outcome and render patient management more efficient.
complex to miRNA target sites in the 3′-untranslated region of mRNA, which leads to mRNA degradation or the inhibition of translation. miRNAs participate in many essential biological processes, including proliferation, differentiation, apoptosis, necrosis, autophagy and stress responses. miRNAs also play a crucial role in cancer pathogenesis through their functions as oncogenes or tumour suppressors depending on their gene targets. In fact, aberrant expression of various miRNAs has been reported during the transformation from BO to OAC.

More importantly, recent evidence has emerged that miRNAs can be secreted from cells, are in circulation or can be taken up by other cells. Because unprotected miRNAs are sensitive to degradation by RNases present in blood, stably encapsulated in extracellular vesicles. Circulating miRNAs are desirable candidates as non-invasive biomarkers for diagnosis, prognosis and prediction in cancer management. Therefore, circulating miRNA profiling could also improve the risk stratification for the progression of BO to OAC. However, because expression levels of circulating miRNAs are affected by various systemic conditions such as age, sex and obesity, it is difficult to clarify just by human observational study whether OAC-specific circulating miRNA expression profiles are derived from the tissue expression profiles of OAC. Therefore, we investigated circulating miRNA levels in a mouse model of BO. Subsequently, we validated the presence of circulating miRNA using a published human circulating miRNA dataset.

METHODS

Animals

L2-IL-1β mice were kindly provided by Dr Timothy C Wang of Columbia University Medical Center, New York. L2-IL-1β mice that are 28 and 46 weeks old (n=2 for each) were sacrificed by cervical dislocation, their oesophagus and stomachs were dissected and sera were obtained. Animal experiments were performed under the approval of the Animal Research Committee of Keio University School of Medicine.

Histological examination

Specimens of the oesophago-gastric junction in mice were fixed in 10% neutralised buffered formalin, embedded in paraffin and sectioned with a thickness of 5 μm. Sections were dehydrated in a graded series of ethanol solutions. Sections were stained with H&E and observed with a BZ-X700 microscope (Keyence, Tokyo, Japan).

Total RNA extraction

Total RNA, including small RNA, was extracted using the mirVana miRNA isolation kit (Ambion, Austin, Texas, USA) for tissue samples, and miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany) was used for serum samples in accordance with the manufacturer’s instructions. The quality of total RNA was checked on a NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA) and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California, USA). The amount of total RNA of tissue samples was evaluated using NanoDrop 1000, whereas that of serum samples was evaluated using 2100 Bioanalyzer because the RNA concentration was low.

miRNA expression analysis

Comprehensive miRNA expression analysis was performed with 250 ng of total RNA from tissue samples and 40 ng of total RNA from serum samples using a 3D-Gene miRNA labelling kit and a 3D-Gene Mouse miRNA Oligo Chip (Toray Industries, Tokyo, Japan), which are designed to detect 1265 miRNA sequences registered in miRBase release 19 (http://www.mirbase.org/). A miRNA was considered to be present if the corresponding microarray signal was higher than (mean + 2 × SD) the signal of the negative controls, of which the 5% of the top and bottom ranked were eliminated by signal intensity. Once a miRNA was considered present, the mean signal of the negative controls, of which the 5% of the top and bottom ranked were eliminated by signal intensity, was subtracted from the miRNA signal. To normalise the signals among microarrays tested, a global median normalisation method was applied.

Statistical analysis

Hierarchical clustering analysis of miRNAs were performed using Partek Genomics Suite 6.6 (Partek, St. Louis, Missouri, USA). A prediction model using multiple miRNAs associated with the presence of OAC was constructed by logistic regression analysis. The area under the receiver operating characteristic curve (AUC), diagnostic sensitivity and specificity were calculated by receiver operating characteristic (ROC) curve analysis. Two-sided p values of <0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics V.22.

RESULTS

Detecting circulating miRNAs that represent miRNA expression profiles of the progression of BO to OAC in mice

We used human interleukin-1β (IL-1β) transgenic mice (L2-IL-1β mice), generated by targeting the expression of human IL-1β to the oesophagus using the Epstein-Barr virus promoter as a model of BO. Histopathology and gene signatures of this model are reported to resemble human BO. We confirmed that metaplastic glands could be observed at the squamocolumnar junction in 28-week-old L2-IL-1β mice (figure 1A,B). In 46-week-old L2-IL-1β mice, multiple dysplastic glands could be observed at the squamocolumnar junction, although OAC was not developed (figure 1C,D).

We comprehensively analysed tissue and serum miRNA expression profiles of 28-week-old and 46-week-old L2-IL-1β mice using microarray analysis.
Results of miRNA microarrays have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus database with accession code GSE100390. By comparing between 28-week-old and 46-week-old mice, potentially deregulated miRNAs during the progression of BO were investigated (figure 2A). First, we selected all the deregulated miRNAs with fold change of >1.5 between the values of 28-week-old and 46-week-old mice either in tissues or in sera. Second, miRNAs with inversely altered levels in tissues and sera due to ageing were excluded. Finally, miRNAs with levels of <22 in sera after normalisation were excluded as it limits the data reliability of lower signal levels in serum because the level of total RNA is relatively low in the serum. Using this strategy, we identified 20 upregulated miRNAs and 44 downregulated miRNAs in both tissues and sera (figure 2B).

Validation of circulating miRNAs using published human dataset

To expand the mouse result to human, we excluded 39 miRNAs that are not evolutionally conserved in humans (figure 2A). Subsequently, we validated the data from mice using a published dataset of human plasma miRNAs, consisting of eight patients with OAC, eight with BO and six healthy controls (GSE51410).30 Our primitive aim was to identify biomarkers for human early stage OAC, namely intramucosal carcinoma and high-grade dysplasia. However, circulating miRNA profiles in patients with high-grade dysplasia have not been publicly available yet. Therefore, we used dataset of OAC instead of high-grade dysplasia. Since it is necessary that the biomarker of high-grade dysplasia can also detect OAC, validation using dataset of OAC is thought to be meaningful for the identification of biomarkers of high-grade dysplasia.

This dataset analysed plasma expression levels of 175 miRNAs that are present in human plasma samples using Serum/Plasma Focus miRNA PCR panels (Exiqon, Vedbaek, Denmark). Among 25 miRNAs that were identified in mice and conserved in humans, seven miRNAs could not be evaluated because they were not included in the PCR panels. Therefore, plasma levels of 18 miRNA were compared between patients with OAC and those with BO. Of the eight miRNAs that were upregulated in 46-week-old mice compared with 28-week-old mice, two miRNAs were also upregulated in patients with OAC compared with those with BO. Of the 10 miRNAs that were downregulated in 46-week-old mice compared with 28-week-old mice, five miRNAs were also downregulated in patients with OAC compared with those with BO. Thus, seven circulating miRNAs were considered as potential candidates of non-invasive biomarkers for the progression of BO to OAC (table 1).

The clustering heat map revealed more explicit segregation of OAC samples from healthy or BO samples (figure 3A). In addition, seven miRNAs could be categorised into three groups, namely, miR-128-3p and miR-328-3p (group 1); miR-143-3p, miR-144-3p and miR-15a-5p (group 2); and miR-1-3p and miR-133b (group 3), according to their expression profiles (figure 3A). Levels of miRNAs in group 1 were upregulated, whereas levels of miRNAs in groups 2 and 3 were downregulated during the progression from BO to OAC (figure 3B). Levels of miRNAs in group 2 were the highest in patients with BO.
Open Access

we determined the accuracy of these seven miRNAs in discriminating patients with OAC from those without OAC (healthy and BO) using the ROC curve analysis (table 1). Levels of miRNAs in group 1 could achieve the AUC of more than 0.7 to discriminate patients with OAC from those without OAC, although the discriminating accuracy was not statistically significant. When we calculated a predictive index by the combination of seven miRNAs, this index could discriminate patients with OAC more accurately than levels of miRNAs in groups 2 and 3. In addition, by combining groups 1, 2 and 3, the discriminating accuracy could be enhanced, indicating that miRNAs in groups 2 and 3 need to be investigated further as potential candidates of biomarkers.

Although the role of miRNAs has not been investigated in the present study, we could hypothesise its role based on previous studies. In line with our results, miR-128-3p is upregulated in colorectal, pancreatic and gastric adenocarcinoma tissues. However, in prostate cancer, glioma and non-small cell lung cancer (NSCLC), miR-128-3p is downregulated. Tumour-suppressive properties have been explained by the inhibition of Bmi-1. The transcription factor Bmi-1 is essential for promoting self-renewal of several types of normal and cancer stem cells. Because Bmi-1 is overexpressed in gastric and pancreatic

**DISCUSSION**

We identified seven miRNAs in mice tissue and serum samples with expression levels that were compatible with the levels in human plasma. Hierarchical clustering analysis revealed that these seven miRNAs could be categorised into three clusters: miR-128-3p and miR-328-3p (group 1); miR-143-3p, miR-144-3p and miR-15a-5p (group 2); and miR-1-3p and miR-133b (group 3). Levels of miRNAs in group 1 were upregulated in OAC compared with healthy controls or patients with BO and could discriminate OAC from healthy controls or BO comparatively better than levels of miRNAs in groups 2 and 3. In addition, by combining groups 1, 2 and 3, the discriminating accuracy could be enhanced, indicating that miRNAs in groups 2 and 3 need to be investigated further as potential candidates of biomarkers.

Although the role of miRNAs has not been investigated in the present study, we could hypothesise its role based on previous studies. In line with our results, miR-128-3p is upregulated in colorectal, pancreatic and gastric adenocarcinoma tissues. However, in prostate cancer, glioma and non-small cell lung cancer (NSCLC), miR-128-3p is downregulated. Tumour-suppressive properties have been explained by the inhibition of Bmi-1. The transcription factor Bmi-1 is essential for promoting self-renewal of several types of normal and cancer stem cells. Because Bmi-1 is overexpressed in gastric and pancreatic

---

**Figure 2** (A) Flow chart illustration of the experimental design; (B) hierarchical clustering analysis based on selected tissue and serum miRNA profiles obtained from 28-week-old and 46-week-old L2-IL-1β mice. Twenty upregulated and 44 downregulated miRNAs in both tissues and sera in 46-week-old mice compared with 28-week-old mice were selected. miRNAs, microRNAs; T28, tissue miRNAs obtained from 28-week-old mice; T46, tissue miRNAs obtained from 46-week-old mice; S28, serum miRNAs obtained from 28-week-old mice; S46, serum miRNAs obtained from 46-week-old mice.
healthy controls with an AUC of 0.82. However, levels as a biomarker to discriminate early stage NSCLC from alpha gene. Circulating miR-328 has also been reported part, through the upregulation of the protein kinase C ring migratory potential to NSCLC cells, working in

miR-128-3p are downregulated in colorectal cancer, and low miR-328-3p expression tends to correlate with increased number of cancer stem-like cells.40 CD44, a miR-328-3p and miR-133b, categorised in group 3, are known as muscle-specific miRNA and exhibit tumour-suppressive functions.53 54 In L2-IL-1β mice, human IL-1β is overexpressed only in the squamous cell layer of the oesophagus. Downregulation of oesophageal tissue levels of miR-1-3p and miR-133b in this mouse model indicated that IL-1β in mucosal layer may affect the muscle layer, leading to the deregulation of muscle-specific miRNAs. We have previously reported that miR-1-3p, miR-133a and miR-133b levels are decreased by H. pylori infection in mice gastric tissues, leading to impaired gastric motility.56 Because IL-1 expression is enhanced in gastric mucosa by H. pylori infection,56,57 the deregulation of muscle-specific miRNAs in these two animal models may be due to the same aetiology.

So far, several other circulating miRNAs have been employed to detect OAC (table 2). In addition, some miRNAs have been reported as prognostic biomarkers of OAC. Zhai et al59 reported that a combination of two circulating miRNA (low miR-3935 expression and high miR-4286 expression) risk score exhibits greater risk for worse overall survival (HR=2.22) than the independent levels of high miR-3935 expression or low miR-4286 expression. Odenthal et al60 reported that low miR-302c and high miR-222 expression is significantly correlated to worse overall survival (log-rank test, p<0.01). Moreover, we have previously reported that miR-222 expression levels are enhanced during exposure to bile acid in the oesophageal epithelial cells, which leads to the

cancer.37 miR-128-3p may be compensatory upregulated to suppress Bmi-1 expression in adenocarcinoma tissues.

Table 1 Circulating microRNA candidates that represent the development of OAC from BO

| Tissue       | Serum       | Human plasma |
|--------------|-------------|--------------|
|             | 28 wk | 46 wk | 28 wk | 46 wk | BO (mean±SD) | OAC (mean±SD) | AUC (95% CI) |
| miR-128-3p   | 24.2   | 39.6   | 144.1 | 377.5 | 1.04±0.13   | 1.25±0.26   | 0.72 (0.49 to 0.96) |
| miR-328-3p   | 37.5   | 44.4   | 160.9 | 314.6 | 0.84±0.13   | 1.06±0.24   | 0.70 (0.44 to 0.96) |
| miR-143-3p   | 7746.3 | 6812.1 | 259.3 | 123.9 | 1.36±0.69   | 1.15±0.44   | 0.51 (0.26 to 0.76) |
| miR-144-3p   | 198.4  | 16.5   | 315.2 | 101.9 | 1.47±0.7    | 1.37±1.12   | 0.58 (0.30 to 0.86) |
| miR-15a-5p   | 581.7  | 497.9  | 2235.4| 945.9 | 1.13±0.14   | 0.99±0.16   | 0.68 (0.44 to 0.92) |
| miR-1-3p     | 7409.4 | 7341.3 | 575.8 | 51.4  | 0.61±0.30   | 0.51±0.25   | 0.66 (0.42 to 0.90) |
| miR-133b     | 5745.7 | 5388.8 | 777.2 | 164.5 | 0.71±0.55   | 0.70±0.28   | 0.50 (0.24 to 0.76) |
| 7-miR combi. (predictive index) | N.A. |       |       |       | 0.13±0.11   | 0.64±0.32   | 0.91 (0.77 to 1.00) |

Grouping was performed based on hierarchical clustering analysis shown in figure 3A. Bold value, statistically significant (p<0.05). AUC, area under the receiver operating characteristic curve to discriminate patients with OAC from those without OAC; BO, Barrett’s oesophagus; IL-1β, interleukin-1β; N. A., not applicable; OAC, oesophageal adenocarcinoma; wk, week.
proteasomal degradation of tumour-suppressive protein Cdx2. Therefore, it would be reasonable to conclude that high levels of miR-222 are associated with poor prognosis. However, these reports are small-scale pilot studies, including our study; therefore, well-validated large-scale biomarker studies are warranted.

Since circulating miRNA status in patients with high-grade dysplasia has not been reported, it has been unknown that our results also fit for the biomarker of high-grade dysplasia. According to reported tissue miRNA profiles, miRNA signatures of high-grade dysplasia were similar to those of OAC as compared with the signatures of non-dysplastic BO and normal squamous epithelium. Interestingly, tissue miRNA profiles of BO adjacent to high-grade dysplasia were also similar to those of high-grade dysplasia and OAC. Therefore, we could expect

**Figure 3**  (A) Hierarchical clustering analysis based on human plasma miRNA profiles obtained from patients with OAC (n=8), with BO (n=8) and without BO (n=6). (B) The average of normalised signal intensity used in the heat map. (C) Dot plots show that plasma levels of miR-128-3p and miR-328 and a predictive index calculated from the levels of seven miRNAs (miR-128-3p, miR-328-3p, miR-143-3p, miR-144-3p, miR-15a-5p, miR-1-3p and miR-133b) were higher in patients with OAC (upper panels). ROC curves show the discrimination accuracy for discriminating patients with OAC from those without OAC using plasma levels of miR-128-3p, miR-328 or a predictive index calculated from levels of seven miRNAs (lower panels). Red bar, median; black arrows, optimum cut-off points to calculate sensitivity and specificity. AUC, area under the receiver operating characteristic curve; BO, Barrett's oesophagus; OAC, oesophageal adenocarcinoma; Sen., sensitivity; Spe., specificity. 

that circulating miRNA profiles of high-grade dysplasia might also be similar to those of OAC. To consider early-stage biomarkers for OAC, this issue must be intensively evaluated in future. In conclusion, seven circulating miRNAs (miR-128-3p, miR-328-3p, miR-143-3p, miR-144-3p, miR-15a-5p, miR-1-3p and miR-133b), consisting of three different characteristic miRNA groups, were identified as promising non-invasive biomarkers to evaluate the carcinogenesis from BO to OAC. However, our data were not based on enough number of samples. Although confirmation of data reproducibility and further prospective validations are needed, accumulating knowledge about circulating miRNAs will change future medical practices.

Acknowledgements We would like to thank Dr Timothy C Wang for providing L2-IL-1β mice and Hitoshi Tsugawa, Hideki Mori, Tsuyoshi Yamane and Yuki Kashiwazaki for technical supports and valuable advices.

Contributors Both authors conceived and designed the experiments. JM performed the experiments and analysed the data. JM wrote the paper, and HS revised the paper.

Funding This study was supported by a Grant-in-Aid for Young Scientists (B) (26860527; to JM), a Grant-in-Aid for Scientific Research B (16H05291; to HS) from the Japan Society for the Promotion of Science (JSPS) (https://www.jsps.go.jp/english/), MEXT-Supported Program for the Strategic Research Foundation at Private Universities (S1411003; to HS) (http://www.mext.go.jp/en/presse/release/1317526.htm), a grant from Takeda Science Foundation (to JM), the Princess Takamatsu Cancer Research grants (to HS) and the Medical School Faculty and Alumni Grant from Keio University Medical Science Fund (to JM and HS).

Disclaimer The funders have no roles in study design, data collection, data analysis, data interpretation or drafting the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Competing interests During the last 2 years, HS received scholarship funds for the research from Daiichi-Sankyo Co., EA Pharma Co., Otsuka Pharmaceutical Co. Ltd and Tsumura Co. and received service honoraria from Astellas Pharma Inc., Astra-Zeneca K.K., EA Pharma Co., Otsuka Pharmaceutical Co. Ltd, Daiichi-Sankyo Co., Takeda Pharmaceutical Co. Ltd, Mylan EPD, Co., Tsumura Co. and Zeria Pharmaceutical Co. Ltd.

Table 2 Previously reported circulating microRNA (miRNA) for the diagnosis of OAC and/or BO

| Authors          | Cases     | Controls | Combination of miRNA                  | AUC  | Sen. | Spe. |
|------------------|-----------|----------|----------------------------------------|------|------|------|
| Bus et al        | OAC       | Healthy  | miR-133a-3p, miR-382-5p, miR-451a        | 0.85 | 0.86 | 0.8  |
| Bus et al        | BO        | Healthy  | miR-133a-3p, miR-136-5p, miR-382-5p      | 0.8  | 0.81 | 0.78 |
| Chiam et al      | OAC       | Healthy  | RNU6-1, miR-16-5p, miR-25-3p, miR-320a, let-7e-5p, miR-15b-5p, miR-30a-5p, miR-324-5p, miR-17-5p, miR-194-5p | 0.99 | ND   | ND   |
| Zhai et al       | OAC       | Healthy  | miR-187, miR-1912, miR-3692, miR-3679-5p, miR-1273d, miR-625, miR-200b, miR-4290, miR-591, miR-125a-3p, miR-3147, miR-4267, miR-640, miR-3652, miR-551b, miR-4323, miR-3714, miR-593 | ND   | ND   | ND   |
| Zhang et al      | OAC       | Healthy  | miR-25-3p, miR-151a-3p, miR-100-5p, miR-375 | ND   | ND   | ND   |
| Cabibi et al     | BO        | Oesophagitis | miR-143, miR-145, miR-194, miR-215, miR-2-4, miR-205 | ND   | ND   | ND   |

AUC, area under the receiver operating characteristic curve; BO, Barrett’s oesophagus; ND, not described; OAC, oesophageal adenocarcinoma; Sen., sensitivity; Spe., specificity.

Provenance and peer review Commissioned; externally peer reviewed.

Data sharing statement All relevant data are within the paper and its supporting materials.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. *Gastroenterology* 2015;148:302–17.
2. Matsuzaki J, Suzuki H, Kobayakawa M, et al. Association of visceral fat area, smoking, and alcohol consumption with reflux esophagitis and Barrett’s esophagus in Japan. *PLoS One* 2015;10:e0133865.
3. Matsuzaki J, Suzuki H, Asakura K, et al. Etiological difference between ultrashort- and short-segment Barrett’s esophagus. *J Gastroenterol* 2011;46:332–8.
4. Matsuzaki J, Suzuki H, Asakura K, et al. Gallstones increase the prevalence of Barrett’s esophagus. *J Gastroenterol* 2010;45:171–8.
5. Fischbach LA, Graham DY, Kramer JR, et al. Association between Helicobacter pylori and Barrett’s esophagus: a case-control study. *Am J Gastroenterol* 2014;109:357–68.
6. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. *N Engl J Med* 2011;365:1375–83.
7. Corley DA, Mehtani K, Quezenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. *Gastroenterology* 2013;145:312–9.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281–97.
9. Nishizawa T, Suzuki H. The role of microRNA in gastric malignancy. *Int J Mol Sci* 2013;14:9487–96.
10. Saito Y, Suzuki H, Matsuura M, et al. MicroRNAs in Hepatobiliary and Pancreatic Cancers. *Front Genet* 2011;2:266.
11. Saito Y, Suzuki H, Hibi T. The role of microRNAs in gastrointestinal cancers. *J Gastroenterol* 2009;44(Suppl 19):15–22.
12. Matsuzaki J, Suzuki H. MicroRNAs in Barrett’s esophagus: future prospects. *Front Genet* 2014;5:69.
13. Feber A, Xi L, Lukeitch JD, et al. MicroRNA expression profiles of esophageal cancer. *J Thorac Cardiovasc Surg* 2008;135:255–60. Discussion 60.

14. Kan T, Sato F, To T, et al. The miR-10b-25 polyicosyn, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. *Gastroenterology* 2009;136:689–700.

15. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett’s esophageal carcinogenesis. *Genes Chromosomes Cancer* 2012;51:473–9.

16. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett’s carcinogenesis. *Int J Cancer* 2011;129:1661–70.

17. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. *Cancer Prev Res* 2013;6:196–205.

18. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. *Clin Cancer Res* 2009;15:5744–52.

19. Matsuzaki J, Suzuki H, Tsugawa H, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. *Gastroenterology* 2013:143:10–11.

20. Bansai A, Gupta V, Wang K. MicroRNA Expression Signatures During Malignant Progression From Barrett’s Esophagus. *J Cell Biochem* 2016;117:1288–93.

21. Kosaka N, Iuchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem* 2010;285:17442–52.

22. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007;9:654–9.

23. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A* 2011;108:3003–8.

24. Vickers KC, Palmissano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol* 2011;13:423–33.

25. Matsuzaki J, OOkoy JD. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. *Int J Clin Oncol* 2017;22:413–20.

26. Shimomura A, Shinoh S, Kawachi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. *Cancer Sci* 2010;101:2926–34.

27. Karolina DS, Tavintinharan S, Arumugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. *J Clin Endocrinol Metab* 2012;97:E2271–E2276.

28. Thomou T, Mori MA, Dreyfuss JM, et al. Adipose-derived circulating microRNAs regulate gene expression in other tissues. *Nature* 2017;542:450–5.

29. Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. *Cancer Cell* 2012;21:36–51.

30. Bus P, Kestler M, Kate FU, et al. Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma. *J Gastroenterol* 2016;51:560–70.

31. Volinia S, Calin GA, Liu CG, et al. A MicroRNA expression signature of human solid tumors defines cancer gene targets. *Oncology* 2007;72:397–402.

32. Chen X, Guo Z, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. *Carcinogenesis* 2009;30:1285–92.

33. Borralho PM, Simoes AE, Gomes SE, et al. miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. *PLoS One* 2011;6:e23787.

34. Iwata Y, Yokobori T, Nishida N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. *Carcinogenesis* 2012;33:2391–7.

35. Oifr M, Hacohen D, Ginsberg D. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F2-induced proliferation by targeting cyclin E. *Mol Cancer Res* 2011;9:440–7.

36. Bonci D, Coccopa V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. *Nat Med* 2008;14:1271–7.

37. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. *Int J Cancer* 2008;123:372–9.

38. Saito K, Caruso S, Bazan V, et al. Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. *OncoTarget* 2016;7:47821–30.

39. Kojima S, Chiyomaru T, Kawakami K, et al. Tumor suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. *Br J Cancer* 2012;106:405–13.

40. Kano M, Seki N, Kikkawa N, et al. MicroRNA expression profiling of esophageal cancer. *PLoS One* 2012;7:e35899.

41. Miyake K, Yonesaki K, Ono T, et al. MicroRNA expression during metaplastic transformation of the esophagus. *Cancer Prev Res* 2011;4:133b: Tumor-suppressive miRNAs target FSCN1 in esophageal cancer cells and promote redox adaptation. *Carcinogenesis* 2012;33:2171–8.

42. Matsuzaki J, Suzuki H. Role of MicroRNAs in esophageal cancer. *BMJ Open Gastro* 2017;4:e000160. doi:10.1136/bmjgast-2017-000160